Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified BV-AVD-R in Chinese Children With Intermediate- and High-risk Classical Hodgkin's Lymphoma
NCT06201507Phase 2Enrolling by invitation
- Sponsor
- Beijing Children's Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by Beijing Children's Hospital. Started Oct 2022; status: enrolling by invitation.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06201507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06201507.